Document Detail

Safety experience with caspofungin in pediatric patients.
MedLine Citation:
PMID:  19779392     Owner:  NLM     Status:  In-Process    
We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.
Theoklis Zaoutis; Thomas Lehrnbecher; Andreas H Groll; William J Steinbach; Hasan S Jafri; Johan Maertens; Angela L Ngai; Joseph W Chow; Arlene F Taylor; Kim M Strohmaier; Michael Bourque; Susan K Bradshaw; Maria Petrecz; Nicholas A Kartsonis
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Pediatric infectious disease journal     Volume:  28     ISSN:  1532-0987     ISO Abbreviation:  Pediatr. Infect. Dis. J.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8701858     Medline TA:  Pediatr Infect Dis J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1132-5     Citation Subset:  IM    
Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Congenital Transmission of Human Immunodeficiency Virus, Cytomegalovirus, and Toxoplasmosis in a Pre...
Next Document:  Laryngeal Involvement in Two Severe Cases of Childhood Tuberculosis.